Xiu-Feng Liu
Overview
Explore the profile of Xiu-Feng Liu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
96
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhang T, Liu X, Chen S, Wang Y
Int J Pediatr Otorhinolaryngol
. 2024 May;
181:111991.
PMID: 38815347
Objective: To investigate whether the child-centered treatment significantly increased satisfaction as revealed by CBCL scores and decreased duration of nasal endoscopy. Methods: A total of 206 pediatric patients were selected...
2.
Jin Z, Chen J, Zhu X, Duan X, Xin Y, Zhong B, et al.
EClinicalMedicine
. 2024 May;
72:102622.
PMID: 38745965
Background: The role of transarterial chemoembolization (TACE) in the treatment of advanced hepatocellular carcinoma (HCC) is unconfirmed. This study aimed to assess the efficacy and safety of immune checkpoint inhibitors...
3.
Yang C, Pan Y, Ye F, Zhu X, Xue J, Li X, et al.
Front Immunol
. 2024 May;
15:1310239.
PMID: 38711515
Background: For decades, stratification criteria for first-line clinical studies have been highly uniform. However, there is no principle or consensus for restratification after systemic treatment progression based on immune checkpoint...
4.
Liang Y, Chen Q, Xu J, Liu X, Xia J, Liu L, et al.
Eur J Cancer
. 2023 Aug;
191:112965.
PMID: 37540921
Purpose: The safety and objective clinical responses were observed in the phase I study using adjuvant autologous tumour-infiltrating lymphocytes (TILs) following concurrent chemoradiotherapy (CCRT) in nasopharyngeal carcinoma (NPC) patients. Methods...
5.
Huang H, Nie C, Liu X, Song B, Yue J, Xu J, et al.
J Clin Invest
. 2022 Jun;
132(15).
PMID: 35727633
BACKGROUNDAdoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TILs) has achieved remarkable clinical efficacy in metastatic cancers such as melanoma and cervical cancer (CC). Here, we explored the safety, feasibility, and...
6.
Li L, Fan M, Li Y, Huang Y, Liu X, Liu J
J Food Drug Anal
. 2022 Jun;
28(2):273-282.
PMID: 35696112
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is an attractive target for new cholesterol-lowering drug development. Here, we developed a method integrating ligand fishing, HPLC-Q-TOF-MS and interdisciplinary assay, aiming to explore...
7.
Zhang Y, Chao J, Liu X, Qin S
World J Clin Cases
. 2019 Oct;
7(19):3104-3110.
PMID: 31624761
Background: Neurofibromatosis type I (NF1) is the most frequent subtype of neurofibromatosis. Its related tumor-suppressor syndromes are characterized by a predisposition to multiple tumor types and other disorder presentations. In...
8.
The correlation between possible RBD and cognitive function in Parkinson's disease patients in China
Yan Y, Lei K, Li Y, Liu X, Chang Y
Ann Clin Transl Neurol
. 2019 May;
6(5):848-853.
PMID: 31139682
Objective: Cognitive impairment is an important symptom of Parkinson's disease (PD) and seriously affects patients' quality of life and prognosis. However, its cause is still uncertain. In about one-third of...
9.
Li J, Wang M, Zhang B, Wu X, Lin T, Liu X, et al.
World J Gastroenterol
. 2018 Dec;
24(46):5189-5202.
PMID: 30581268
Tyrosine kinase inhibitors (TKIs) have improved the overall survival of patients with gastrointestinal stromal tumors (GISTs), but their side effects can impact dose intensity and, consequently, the clinical benefit. To...
10.
Li L, Kong J, Yao C, Liu X, Liu J
J Pharm Biomed Anal
. 2018 Nov;
164:241-248.
PMID: 30396051
The urokinase plasminogen activator (uPA) is regarded as the crucial trigger for plasmin generation, which is involved in several diseases especially for neoplasm metastasis. In this study, an efficient approach...